Compare PZZA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | VALN |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 875.7M |
| IPO Year | 1995 | 2021 |
| Metric | PZZA | VALN |
|---|---|---|
| Price | $33.82 | $10.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $45.00 | $15.75 |
| AVG Volume (30 Days) | ★ 1.7M | 17.4K |
| Earning Date | 05-07-2026 | 03-18-2026 |
| Dividend Yield | ★ 5.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $2,068,421,000.00 | N/A |
| Revenue This Year | N/A | $4.00 |
| Revenue Next Year | N/A | $92.04 |
| P/E Ratio | $38.17 | ★ N/A |
| Revenue Growth | ★ 14.07 | N/A |
| 52 Week Low | $30.16 | $5.43 |
| 52 Week High | $55.74 | $12.25 |
| Indicator | PZZA | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 47.04 |
| Support Level | $33.30 | $9.85 |
| Resistance Level | $34.89 | $10.46 |
| Average True Range (ATR) | 1.97 | 0.42 |
| MACD | 0.32 | -0.08 |
| Stochastic Oscillator | 37.26 | 18.08 |
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.